Amgen (AMGN) closed at $270.90 in the latest trading session, marking a +0.76% move from the prior day. This move outpaced the S&P 500's daily gain of 0.63%. Meanwhile, the Dow gained 0.2%, and the Nasdaq, a tech-heavy index, added 0.82%.

Heading into today, shares of the world's largest biotech drugmaker had lost 5.23% over the past month, lagging the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76% in that time.

The investment community will be closely monitoring the performance of Amgen in its forthcoming earnings report. The company is predicted to post an EPS of $3.84, indicating a 3.52% decline compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $7.45 billion, up 21.98% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $19.48 per share and a revenue of $32.91 billion, demonstrating changes of +4.45% and +16.75%, respectively, from the preceding year.

Investors should also pay attention to any latest changes in analyst estimates for Amgen. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.16% decrease. Amgen currently has a Zacks Rank of #3 (Hold).

In terms of valuation, Amgen is presently being traded at a Forward P/E ratio of 13.8. This denotes a discount relative to the industry's average Forward P/E of 24.2.

We can also see that AMGN currently has a PEG ratio of 2.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.58 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 71, positioning it in the top 29% of all 250+ industries.